Work

Supplementary Table S4 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

Year: 2026

Type: supplementary-materials

Abstract: Best change in clinical symptom assessment (mITT set).

DOI: 10.1158/1078-0432.33253407

Authors: Chen Hua, Zhuli Wu, Xingli Wang, Huilong Liu, Ben Li, Yang Zheng, Xiaoxi Lin

Language: English

Topic: Vascular Malformations and Hemangiomas

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7203488025

Cites:

Cited by:

Related to: 10